Oasmia Pharmaceutical AB has received approval from the regulatory authorities
in Germany and Austria to start a clinical study of Doxophos® Vet in dogs. The
study will start in the summer.
Uppsala, Sweden, 2011-06-09 08:49 CEST (GLOBE NEWSWIRE) -- The study is the next step in the clinical development of Doxophos® Vet, with the aim to market Doxophos® Vet as treatment of lymphoma in dogs.
Doxophos® Vet is Oasmia's second product candidate within Animal Health and is a novel patented formulation of doxorubicin. Doxorubicin is one of the most effective and commonly used substances within human cancer medicine. In veterinary oncology, it is also used to great extent. At this point in time however, there are no registered veterinary pharmaceuticals containing doxorubicin and veterinarians are forced to use adapted methods using pharmaceuticals intended for human use.
- There is a great need for this type of pharmaceutical for dogs with a terminal tumour disease, as doxorubicin has shown a good effect but also severe side effects. Currently, there is no registered pharmaceutical based on doxorubicin for dogs, and it is very important to have a thorough investigation of efficacy and safety in the species you aim to treat. This investigation is essential to optimize the treatment for a large group of patients within veterinary medicine, such as dogs with severe tumour disease, says Dr Henrik von Euler, oncologist at SLU and Chief Medical Officer at Oasmia.
About Doxophos® Vet The active substance in Doxophos® Vet is doxorubicin, one of the most used cytotoxic substances in the world. Doxorubicin shows a good efficacy, but may also cause permanent damage to the heart due to immediate high exposure to doxorubicin through intravenous administration. In Doxophos® Vet, doxorubicin forms an insoluble salt with the novel excipient XR-17 which subsequently forms nanoparticle-sized micelles when reconstituted in a suitable aqueous solvent. This exempts the high exposure and the effect becomes longer. The hypothesis behind the development of Doxophos® Vet is that the risk for a serious heart effect is lowered and a higher dose can be given with a better effect.
About Oasmia Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden.
Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. German contact : Dr Sönke Knop, Peggy Kropmanns, edicto, GmbH, Frankfurt, Deutschland E-Mail: oasmia@edicto.de Phone: +49 (0) 69 90 55 05 51 Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=352581
Uppsala, Sweden, 2011-06-09 08:49 CEST (GLOBE NEWSWIRE) -- The study is the next step in the clinical development of Doxophos® Vet, with the aim to market Doxophos® Vet as treatment of lymphoma in dogs.
Doxophos® Vet is Oasmia's second product candidate within Animal Health and is a novel patented formulation of doxorubicin. Doxorubicin is one of the most effective and commonly used substances within human cancer medicine. In veterinary oncology, it is also used to great extent. At this point in time however, there are no registered veterinary pharmaceuticals containing doxorubicin and veterinarians are forced to use adapted methods using pharmaceuticals intended for human use.
- There is a great need for this type of pharmaceutical for dogs with a terminal tumour disease, as doxorubicin has shown a good effect but also severe side effects. Currently, there is no registered pharmaceutical based on doxorubicin for dogs, and it is very important to have a thorough investigation of efficacy and safety in the species you aim to treat. This investigation is essential to optimize the treatment for a large group of patients within veterinary medicine, such as dogs with severe tumour disease, says Dr Henrik von Euler, oncologist at SLU and Chief Medical Officer at Oasmia.
About Doxophos® Vet The active substance in Doxophos® Vet is doxorubicin, one of the most used cytotoxic substances in the world. Doxorubicin shows a good efficacy, but may also cause permanent damage to the heart due to immediate high exposure to doxorubicin through intravenous administration. In Doxophos® Vet, doxorubicin forms an insoluble salt with the novel excipient XR-17 which subsequently forms nanoparticle-sized micelles when reconstituted in a suitable aqueous solvent. This exempts the high exposure and the effect becomes longer. The hypothesis behind the development of Doxophos® Vet is that the risk for a serious heart effect is lowered and a higher dose can be given with a better effect.
About Oasmia Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden.
Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. German contact : Dr Sönke Knop, Peggy Kropmanns, edicto, GmbH, Frankfurt, Deutschland E-Mail: oasmia@edicto.de Phone: +49 (0) 69 90 55 05 51 Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=352581